Endocrinology and Metabolism

Original Articles

Diabetes
High Brachial Ankle Pulse Wave Velocity as a Marker for Predicting Coronary Artery Stenosis in Patients with Type 2 Diabetes: Bo Hyun Kim, Jae Sik Jang, Yong Seop Kwon, June Hyung Kim, In Joo Kim, Chang Won Lee; Endocrinol Metab. 2018;33(1):88-96. Published online March 21, 2018; DOI: https://doi.org/10.3803/EnM.2018.33.1.88

4,463 View
55 Download
13 Web of Science
14 Crossref

Background

We evaluated the ability of brachial ankle pulse wave velocity (baPWV) to predict coronary artery stenosis (CAS) in patients with type 2 diabetes, and compared the predictive power of baPWV to that of well-known cardiovascular disease (CVD) risk calculators.

Methods

The study group included 83 consecutive patients over 30 years old with type 2 diabetes who complained of vague chest discomfort. An automatic pulse waveform analyzer was used to measure baPWV. CAS was measured using multi-slice computed tomographic (MSCT) angiography.

Results

Age, maximal baPWV, duration of diabetes, current smoking, the UK Prospective Diabetes Study (UKPDS) Risk Engine score, American College of Cardiology/American Heart Association (ACC/AHA) risk estimator score, the Framingham risk calculator score, and coronary artery calcium score were greater in patients with CAS than in those without CAS. An area under the curve (AUC) indicative of a predictive value for CAS (≥20%) was found for several parameters. The AUC of maximal baPWV, the UKPDS Risk Engine, the ACC/AHA ASCVD risk estimator, and the Framingham risk calculator were 0.672 (95% confidence interval [CI], 0.554 to 0.785; P=0.010), 0.777 (95% CI, 0.675 to 0.878; P<0.001), 0.763 (95% CI, 0.660 to 0.866; P<0.001), and 0.736 (95% CI, 0.629 to 0.843; P<0.001), respectively. The optimal cutoff value of baPWV for the detection of CAS was 1,650 cm/sec (sensitivity, 68.9%; specificity, 63.2%).

Conclusion

Maximal baPWV was closely related with CAS detected by MSCT coronary angiography in patients with type 2 diabetes. baPWV has the potential to be a useful, noninvasive screening tool for the prediction of occult CAS in patients with type 2 diabetes.

Citations

Citations to this article as recorded by

Polyvinyl Alcohol Phantoms With Heterogeneous Plaques: Estimation of Pulse Wave Velocity at the Stenotic Region Using Pulse Wave Imaging
Nima Mobadersany, Pengcheng Liang, Paul Kemper, Elisa E. Konofagou
Ultrasound in Medicine & Biology.2024; 50(1): 91. CrossRef
The risk factors of early arterial stiffness in type 2 diabetes without diabetic macroangiopathy
Jia-Hui Wu, Rui Wang, Xiao-Jiao Jia, Na Lu, Qiang Lu, Fu-Zai Yin, Chun-Ming Ma
International Journal of Diabetes in Developing Countries.2023;[Epub] CrossRef
Arterial Stiffness as a Predictor of the Index of Atherosclerotic Cardiovascular Disease in Hypertensive Patients
Guili Chang, Yueliang Hu, Qian Ge, Shaoli Chu, Alberto Avolio, Junli Zuo
International Journal of Environmental Research and Public Health.2023; 20(4): 2832. CrossRef
Pulse wave imaging of a stenotic artery model with plaque constituents of different stiffnesses: Experimental demonstration in phantoms and fluid-structure interaction simulation
Nima Mobadersany, Nirvedh H. Meshram, Paul Kemper, C.V. Sise, Grigorios M. Karageorgos, Pengcheng Liang, Gerard A. Ateshian, Elisa E. Konofagou
Journal of Biomechanics.2023; 149: 111502. CrossRef
Computational clustering reveals differentiated coronary artery calcium progression at prevalent levels of pulse wave velocity by classifying high-risk patients
Maximo Rousseau-Portalis, Leandro Cymberknop, Ignacio Farro, Ricardo Armentano
Frontiers in Cardiovascular Medicine.2023;[Epub] CrossRef
Pepsinogen ratio and brachial-ankle pulse wave velocity: a cross-sectional study on their interrelationship in atherosclerosis
Yuexi Li, Xiaoqin Liu, Yuhan Luo, Qiaoli Wang
BMC Cardiovascular Disorders.2023;[Epub] CrossRef
The Plasma Atherogenic Index is an Independent Predictor of Arterial Stiffness in Healthy Koreans
Ji Sun Nam, Min Kyung Kim, Kahui Park, Arim Choi, Shinae Kang, Chul Woo Ahn, Jong Suk Park
Angiology.2022; 73(6): 514. CrossRef
Risk assessment indicators and brachial-ankle pulse wave velocity to predict atherosclerotic cardiovascular disease
Hung-Ju Ko, Chuan-Chuan Liu, Po-Jui Hsu, Kuang-Chun Hu, Chung-Lieh Hung, Lo-Yip Yu, Yun-Chieh Huang, Shou-Chuan Shih
Medicine.2022; 101(32): e29609. CrossRef
Brachial-ankle pulse wave velocity as a predictor of long-term cardiovascular events in 2174 subjects with type 2 diabetes mellitus: A retrospective cohort study
Hack-Lyoung Kim, Won Kyeong Jeon, Hyun Sung Joh, Woo-Hyun Lim, Jae-Bin Seo, Sang-Hyun Kim, Joo-Hee Zo, Myung-A Kim
Medicine.2022; 101(45): e31758. CrossRef
Ultrasound Methods in the Evaluation of Atherosclerosis: From Pathophysiology to Clinic
Gabriel Cismaru, Teodora Serban, Alexandru Tirpe
Biomedicines.2021; 9(4): 418. CrossRef
A model to predict risk of stroke in middle-aged adults with type 2 diabetes generated from a nationwide population-based cohort study in Korea
Mee-Kyoung Kim, Kyungdo Han, Jae-Hyoung Cho, Hyuk-Sang Kwon, Kun-Ho Yoon, Seung-Hwan Lee
Diabetes Research and Clinical Practice.2020; 163: 108157. CrossRef
Association of impaired arterial wall properties with the presence of coronary artery disease in patients with abdominal aortic aneurysms
Pinelopi Rafouli‐Stergiou, Ignatios Ikonomidis, Niki Katsiki, Nikolaos P. E. Kadoglou, Stefanos Vlachos, John Thymis, John Parissis, Konstantinos G. Moulakakis, John D. Kakisis
The Journal of Clinical Hypertension.2020; 22(2): 187. CrossRef
Association of serum FAM19A5 with metabolic and vascular risk factors in human subjects with or without type 2 diabetes
You-Bin Lee, Hwan-Jin Hwang, Jung A Kim, Soon Young Hwang, Eun Roh, So-hyeon Hong, Kyung Mook Choi, Sei Hyun Baik, Hye Jin Yoo
Diabetes and Vascular Disease Research.2019; 16(6): 530. CrossRef
Pulse Wave Velocity in Atherosclerosis
Hack-Lyoung Kim, Sang-Hyun Kim
Frontiers in Cardiovascular Medicine.2019;[Epub] CrossRef

Clinical Study
Effects of Short-Term Exenatide Treatment on Regional Fat Distribution, Glycated Hemoglobin Levels, and Aortic Pulse Wave Velocity of Obese Type 2 Diabetes Mellitus Patients: Ju-Young Hong, Keun-Young Park, Byung-Joon Kim, Won-Min Hwang, Dong-Ho Kim, Dong-Mee Lim; Endocrinol Metab. 2016;31(1):80-85. Published online March 16, 2016; DOI: https://doi.org/10.3803/EnM.2016.31.1.80

4,973 View
49 Download
26 Web of Science
22 Crossref

Abstract PDF PubReader

Background

Most type 2 diabetes mellitus patients are obese and have obesity related vascular complications. Exenatide treatment is well known for both decreasing glycated hemoglobin levels and reduction in body weight. So, this study aimed to determine the effects of exenatide on body composition, glycated hemoglobin levels, and vascular stiffness in obese type 2 diabetes mellitus patients.

Methods

For 1 month, 32 obese type 2 diabetes mellitus patients were administered 5 µg of exenatide twice daily. The dosage was then increased to 10 µg. Patients' height, body weight, glycated hemoglobin levels, lipid profile, pulse wave velocity (PWV), body mass index, fat mass, and muscle mass were measured by using Inbody at baseline and after 3 months of treatment.

Results

After 3 months of treatment, glycated hemoglobin levels decreased significantly (P=0.007). Triglyceride, total cholesterol, and low density lipoprotein levels decreased, while aspartate aminotransferase and alanine aminotransferase levels were no change. Body weight, and fat mass decreased significantly (P=0.002 and P=0.001, respectively), while interestingly, muscle mass did not decrease (P=0.289). In addition to, Waist-to-hip ratio and aortic PWV decreased significantly (P=0.006 and P=0.001, respectively).

Conclusion

Effects of short term exenatide use in obese type 2 diabetes mellitus with cardiometabolic high risk patients not only reduced body weight without muscle mass loss, body fat mass, and glycated hemoglobin levels but also improved aortic PWV in accordance with waist to hip ratio.

Citations

Citations to this article as recorded by

Adipose tissue inflammation linked to obesity: A review of current understanding, therapies and relevance of phyto-therapeutics
Christiana Eleojo Aruwa, Saheed Sabiu
Heliyon.2024; 10(1): e23114. CrossRef
Separate and combined effects of empagliflozin and semaglutide on vascular function: A 32‐week randomized trial
Liv Vernstrøm, Søren Gullaksen, Steffen S. Sørensen, Kristian L. Funck, Esben Laugesen, Per L. Poulsen
Diabetes, Obesity and Metabolism.2024; 26(5): 1624. CrossRef
Diabetic Sarcopenia. A proposed muscle screening protocol in people with diabetes
Daniel de Luis Román, Juana Carretero Gómez, José Manuel García-Almeida, Fernando Garrachón Vallo, German Guzmán Rolo, Juan José López Gómez, Francisco José Tarazona-Santabalbina, Alejandro Sanz-Paris
Reviews in Endocrine and Metabolic Disorders.2024;[Epub] CrossRef
The Current Landscape of Pharmacotherapies for Sarcopenia
Gulistan Bahat, Serdar Ozkok
Drugs & Aging.2024; 41(2): 83. CrossRef
Vascular Aging: Assessment and Intervention
Ao Li, Jinhua Yan, Ya Zhao, Zhenping Yu, Shane Tian, Abdul Haseeb Khan, Yuanzheng Zhu, Andong Wu, Cuntai Zhang, Xiao-Li Tian
Clinical Interventions in Aging.2023; Volume 18: 1373. CrossRef
The Effect of Additional Treatment with Empagliflozin or Semaglutide on Endothelial Function and Arterial Stiffness in Subjects with Type 1 Diabetes Mellitus—ENDIS Study
Maja Preložnik Navodnik, Andrej Janež, Ivan Žuran
Pharmaceutics.2023; 15(7): 1945. CrossRef
Sarcopenia as a Little-Recognized Comorbidity of Type II Diabetes Mellitus: A Review of the Diagnosis and Treatment
Christian Salom Vendrell, Elisa García Tercero, Juan Bautista Moro Hernández, Bernardo Abel Cedeno-Veloz
Nutrients.2023; 15(19): 4149. CrossRef
Oral semaglutide improves body composition and preserves lean mass in patients with type 2 diabetes: a 26-week prospective real-life study
Sara Volpe, Giuseppe Lisco, Margherita Fanelli, Davide Racaniello, Valentina Colaianni, Valentina Lavarra, Domenico Triggiani, Lucilla Crudele, Vincenzo Triggiani, Carlo Sabbà, Giovanni De Pergola, Giuseppina Piazzolla
Frontiers in Endocrinology.2023;[Epub] CrossRef
GLP1 Receptor Agonists—Effects beyond Obesity and Diabetes
Sydney S. Wilbon, Mikhail G. Kolonin
Cells.2023; 13(1): 65. CrossRef
The Effectiveness of GLP-1 Receptor Agonist Semaglutide on Body Composition in Elderly Obese Diabetic Patients: A Pilot Study
Yoshinori Ozeki, Takayuki Masaki, Akari Kamata, Shotaro Miyamoto, Yuichi Yoshida, Mitsuhiro Okamoto, Koro Gotoh, Hirotaka Shibata
Medicines.2022; 9(9): 47. CrossRef
Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus
Juan J. Gorgojo-Martínez, Pedro Mezquita-Raya, Juana Carretero-Gómez, Almudena Castro, Ana Cebrián-Cuenca, Alejandra de Torres-Sánchez, María Dolores García-de-Lucas, Julio Núñez, Juan Carlos Obaya, María José Soler, José Luis Górriz, Miguel Ángel Rubio-H
Journal of Clinical Medicine.2022; 12(1): 145. CrossRef
The Impact of Glucose-Lowering Drugs on Sarcopenia in Type 2 Diabetes: Current Evidence and Underlying Mechanisms
Elena Massimino, Anna Izzo, Gabriele Riccardi, Giuseppe Della Pepa
Cells.2021; 10(8): 1958. CrossRef
Anti‐diabetic drugs and sarcopenia: emerging links, mechanistic insights, and clinical implications
Xueli Zhang, Yi Zhao, Shuobing Chen, Hua Shao
Journal of Cachexia, Sarcopenia and Muscle.2021; 12(6): 1368. CrossRef
Effect of glycemic control on markers of subclinical atherosclerosis in patients with type 2 diabetes mellitus: A review
Sofia Antoniou, Katerina K K Naka, Marios Papadakis, Aris Bechlioulis, Agathocles Tsatsoulis, Lampros K Michalis, Stelios Tigas
World Journal of Diabetes.2021; 12(11): 1856. CrossRef
A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans
Jack Alistair Sargeant, Joseph Henson, James Adam King, Thomas Yates, Kamlesh Khunti, Melanie Jane Davies
Endocrinology and Metabolism.2019; 34(3): 247. CrossRef
The effect of dulaglutide on body composition in type 2 diabetes mellitus patients on hemodialysis
Takahiro Yajima, Kumiko Yajima, Hiroshi Takahashi, Keigo Yasuda
Journal of Diabetes and its Complications.2018; 32(8): 759. CrossRef
Effects of Newer Antidiabetic Drugs on Endothelial Function and Arterial Stiffness: A Systematic Review and Meta-Analysis
Konstantinos Batzias, Alexios S. Antonopoulos, Evangelos Oikonomou, Gerasimos Siasos, Evanthia Bletsa, Panagiota K. Stampouloglou, Chara-Vasiliki Mistakidi, Marina Noutsou, Niki Katsiki, Periklis Karopoulos, Georgios Charalambous, Anastasia Thanopoulou, N
Journal of Diabetes Research.2018; 2018: 1. CrossRef
Regulation of visceral and epicardial adipose tissue for preventing cardiovascular injuries associated to obesity and diabetes
N. González, Z. Moreno-Villegas, A. González-Bris, J. Egido, Ó. Lorenzo
Cardiovascular Diabetology.2017;[Epub] CrossRef
Articles inEndocrinology and Metabolismin 2016
Won-Young Lee
Endocrinology and Metabolism.2017; 32(1): 62. CrossRef
Difference in protective effects of GIP and GLP-1 on endothelial cells according to cyclic adenosine monophosphate response
Dong-Mee Lim, Keun-Young Park, Won-Min Hwang, Ju-Young Kim, Byung-Joon Kim
Experimental and Therapeutic Medicine.2017; 13(5): 2558. CrossRef
Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists
Qiuhe Ji
Clinical Therapeutics.2017; 39(6): 1244. CrossRef
Differential Role of Adipose Tissues in Obesity and Related Metabolic and Vascular Complications
Almudena Gómez-Hernández, Nuria Beneit, Sabela Díaz-Castroverde, Óscar Escribano
International Journal of Endocrinology.2016; 2016: 1. CrossRef

First
Prev
Page of 1
Next
Last

Search